ANASTROZOLE
AROMATASE INHIBITORS · METASTATIC BREAST CARCINOMA ·+2
BRECKENRIDGE
Drug class
Aromatase Inhibitors
Aromatase inhibitors are a class of endocrine therapies that block the cytochrome P450 aromatase enzyme, which catalyzes the peripheral conversion of androgens into estrogens. Read more about Aromatase Inhibitors
52 drugs in this class 36 manufacturers
Drugs in Aromatase Inhibitors
LETROZOLE
AROMATASE INHIBITORS · EARLY BREAST CANCER HORMONE RECEPTOR POSITIVE AND POSTMENOPAUSAL ·+2
SUN PHARMACEUTI
LETROZOLE
AROMATASE INHIBITORS · EARLY BREAST CANCER HORMONE RECEPTOR POSITIVE AND POSTMENOPAUSAL ·+2
TEVA USA
LETROZOLE
AROMATASE INHIBITORS · EARLY BREAST CANCER HORMONE RECEPTOR POSITIVE AND POSTMENOPAUSAL ·+2
BRECKENRIDGE
ANASTROZOLE
AROMATASE INHIBITORS · METASTATIC BREAST CARCINOMA ·+2
APOTEX CORP
LETROZOLE
AROMATASE INHIBITORS · EARLY BREAST CANCER HORMONE RECEPTOR POSITIVE AND POSTMENOPAUSAL ·+2
APOTEX CORP
ANASTROZOLE
AROMATASE INHIBITORS · METASTATIC BREAST CARCINOMA ·+2
BLUEPOINT LABOR
EXEMESTANE
AROMATASE INHIBITORS · ADVANCED BREAST CANCER PROGRESS POST-ANTIESTROGEN THERAPY ·+1
ALVOGEN INC
EXEMESTANE
AROMATASE INHIBITORS · ADVANCED BREAST CANCER PROGRESS POST-ANTIESTROGEN THERAPY ·+1
ROXANE/WEST-WAR
Filter & compare in the drug finder →
Opens the drug finder with Aromatase Inhibitors preselected. Add indication or manufacturer filters there.
Aromatase inhibitors are a class of endocrine therapies that block the cytochrome P450 aromatase enzyme, which catalyzes the peripheral conversion of androgens into estrogens.
By substantially reducing circulating and tissue estrogen concentrations, these agents eliminate the hormonal stimulus that fuels hormone receptor–positive tumor proliferation.
They are primarily utilized in the adjuvant, extended adjuvant, and advanced treatment settings for hormone receptor–positive breast cancer in postmenopausal individuals, as well as in combination with ovarian suppression for premenopausal patients.
-
fda.gov
Aromatase inhibitors are a class of endocrine therapies that block the cytochrome P450 aromatase enzyme, which catalyzes the peripheral conversion of androgens into estrogens By substantially reducing circulating and tissue estrogen concentrations, these agents eliminate the hormonal stimulus that fuels hormone receptor–positive tumor proliferation
-
nih.gov
Aromatase inhibitors are a class of endocrine therapies that block the cytochrome P450 aromatase enzyme, which catalyzes the peripheral conversion of androgens into estrogens By substantially reducing circulating and tissue estrogen concentrations, these agents eliminate the hormonal stimulus that fuels hormone receptor–positive tumor proliferation They are primarily utilized in the adjuvant, extended adjuvant, and advanced treatment settings for hormone receptor–positive breast cancer in postme...
-
fda.gov
They are primarily utilized in the adjuvant, extended adjuvant, and advanced treatment settings for hormone receptor–positive breast cancer in postmenopausal individuals, as well as in combination with ovarian suppression for premenopausal patients
-
hiacode.com
They are primarily utilized in the adjuvant, extended adjuvant, and advanced treatment settings for hormone receptor–positive breast cancer in postmenopausal individuals, as well as in combination with ovarian suppression for premenopausal patients
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.